Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04725188 |
Title | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | Merck Sharp & Dohme Corp. |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS |